Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase-IIa, double-blind, randomized, controlled study on the tolerability and early efficacy of hLF1-11 [human lactoferrin 1-11 peptide] in hospitalized patients with bacteremia due to staphylococcus epidermidis

Next Previous
X
Search
Trial Profile

A phase-IIa, double-blind, randomized, controlled study on the tolerability and early efficacy of hLF1-11 [human lactoferrin 1-11 peptide] in hospitalized patients with bacteremia due to staphylococcus epidermidis

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 14 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lactoferrin 1-11 (Primary)
  • Indications Bacteraemia; Staphylococcal infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LIST
  • Sponsors AM-Pharma

    • Most Recent Events

    • 13 Jan 2010 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 16 Oct 2008 Status changed from not yet recruiting to suspended.
    • 23 Apr 2008 The expected completion date for this trial is now 1 Dec 2008, according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top